TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17924867

Group type: EXPERIMENTAL
Intervention: Acarbose up to 100 mg three times a day
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 15030636

Group type: EXPERIMENTAL
Intervention: Brow tension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head shaking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal smile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cheek tension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nodding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Frown
Number of subjects: 0
Study: 11598842

Group type: EXPERIMENTAL
Intervention: Yeast-derived HPV-11 L1 VLP vaccine
Number of subjects: 104
Study: 9848291

Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no salpingectomy)
Number of subjects: 102
Study: 7863149

Group type: EXPERIMENTAL
Intervention: Hydrocolloidal dressing (HCD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline-soaked gauze
Number of subjects: 30
Study: 2846132

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study: 30844623

Group type: EXPERIMENTAL
Intervention: IATP‐R (Interval aerobic training program with active recovery bouts)
Number of subjects: 60
Study: 29189701

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 66

Group type: COMPARATOR
Intervention: Neutral writing
Number of subjects: 66
Study: 25319731

Group type: EXPERIMENTAL
Intervention: Telaprevir-based triple therapy
Number of subjects: 465
Study: 23726934

Group type: EXPERIMENTAL
Intervention: Participants experiencing pain and required to reach for the switch that would turn off the experimental stimulus.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Other 3 conditions (not specified in detail).
Number of subjects: 18
Study: 21428465

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 118
Study: 19712998

Group type: EXPERIMENTAL
Intervention: Add-on device
Number of subjects: 683

Group type: COMPARATOR
Intervention: Control
Number of subjects: 683
Study: 17509246

Group type: EXPERIMENTAL
Intervention: Disease-modifying drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological markers
Number of subjects: 0
Study: 14711840

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg/12 h)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Teicoplanin (400 mg/12 h for three doses then 400 mg/24 h)
Number of subjects: 202
Study: 11876465

Group type: EXPERIMENTAL
Intervention: Timed ingestion of caffeine and protein foods and adjustment of the sleep/wake cycle
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study: 9415512

Group type: EXPERIMENTAL
Intervention: Coping with chronic low back pain
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Coping constructs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Self, ideal-self, and social-self constructs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Coping vs. being pain-free
Number of subjects: 19
Study: 8103027

Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (up to 600 mg/24 hours)
Number of subjects: 11
Study: 2874761

Group type: EXPERIMENTAL
Intervention: Transient arterial occlusion (blood pressure cuffs inflated to 20 to 40 mm Hg above systolic pressure for 20 seconds)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transient arterial occlusion
Number of subjects: 60
Study: 30595526

Group type: EXPERIMENTAL
Intervention: JR‐141 (iduronate-2-sulfatase fused with anti-human transferrin receptor antibody)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: JR‐141
Number of subjects: 14
Study: 29922714

Group type: EXPERIMENTAL
Intervention: Composite pulse technique for arbitrary one-spin rotations and two-spin controlled-not (CNOT) gate.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite pulse technique for two-spin controlled-not (CNOT) gate.
Number of subjects: 0
Study: 27422891

Group type: EXPERIMENTAL
Intervention: Toreforant 100 mg/day
Number of subjects: 358

Group type: COMPARATOR
Intervention: Toreforant 3/10/30 mg
Number of subjects: 358

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study: 25363176

Group type: EXPERIMENTAL
Intervention: Patients with attached stent to Foley catheter (linked stent group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Patients with conventional technique (stent separated from Foley) (control group)
Number of subjects: 90
Study: 23169286

Group type: EXPERIMENTAL
Intervention: hrHPV testing with liquid-based cytology (LBC) triage of hrHPV positives, exit screen at 4 years
Number of subjects: 18648

Group type: EXPERIMENTAL
Intervention: hrHPV testing with LBC triage of hrHPV positives, exit screen at 2 years
Number of subjects: 18648

Group type: COMPARATOR
Intervention: Liquid based cytology with ASC-US triage and hrHPV testing
Number of subjects: 18648
Study: 20307302

Group type: EXPERIMENTAL
Intervention: Short course (7 sessions, median cumulative duration 111 minutes)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Medium course (12 sessions, median cumulative duration 158 minutes)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Long course (17 sessions, median cumulative duration 223 minutes)
Number of subjects: 158
Study: 18042508

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) with 3 agents for 48 weeks
Number of subjects: 1434

Group type: COMPARATOR
Intervention: Control group (HCV-negative subjects)
Number of subjects: 1434
Study: 16146463

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12133187

Group type: EXPERIMENTAL
Intervention: Physiological-dose steroid therapy for 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard therapy for sepsis
Number of subjects: 40
Study: 10468081

Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (inhibited pacing)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Biatrial pacing vs Right atrial pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control vs Right atrial pacing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control vs Biatrial pacing
Number of subjects: 19
Study: 7540397

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg in CPB priming volume and 7,500 KIU/kg intravenously each hour during CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 20
Study: 2228396

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (30 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 91027

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 192
Study: 31915043

Group type: EXPERIMENTAL
Intervention: Staying UpRight exercise program (strength and balance exercises)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Seated exercise program (control group)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Staying UpRight exercise program
Number of subjects: 528

Group type: COMPARATOR
Intervention: Seated exercise program
Number of subjects: 528
Study: 31658479

Group type: EXPERIMENTAL
Intervention: Interventional treatment strategies for secondary MR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter-based mitral valve prosthesis
Number of subjects: 0
Study: 28148502

Group type: EXPERIMENTAL
Intervention: Intragastric administration of 1 μmol DB/kg
Number of subjects: 39
Study: 26696482

Group type: EXPERIMENTAL
Intervention: Packed group (nasal packing with Merocel)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-packed group (no nasal packing)
Number of subjects: 112
Study: 23953358

Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention
Number of subjects: 357
Study: 21029121

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study: 19144382

Group type: EXPERIMENTAL
Intervention: Virtual microscopy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional glass microscopy
Number of subjects: 14
Study: 16904537

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/l)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ischemic Preconditioning (IP)
Number of subjects: 42
Study: 15167288

Group type: EXPERIMENTAL
Intervention: Triple-nucleoside therapy (ZDV, 3TC, and ddI)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Dual-nucleoside therapy (ZDV and 3TC or ddI and d4T)
Number of subjects: 184
Study: 11384568

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% three times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily
Number of subjects: 30
Study: 9205014

Group type: EXPERIMENTAL
Intervention: Successful rescue PTCA
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Failed rescue PTCA
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Rescue PTCA (successes and failures combined)
Number of subjects: 402

Group type: COMPARATOR
Intervention: No rescue PTCA
Number of subjects: 402

Group type: COMPARATOR
Intervention: Patients with patent arteries
Number of subjects: 402
Study: 7804524

Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 2649
Study: 2885337

Group type: COMPARATOR
Intervention: Insulin alone (25 mU/m2 X min)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Insulin with SRIH (250 micrograms/h) and glucagon replacement (0.4 ng/kg X min)
Number of subjects: 8
Study: 30255302

Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor – MSD; 40 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (simvastatin-untreated)
Number of subjects: 50
Study: 29626465

Group type: EXPERIMENTAL
Intervention: 12-month adjuvant androgen-deprivation therapy (ADT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-adjuvant ADT
Number of subjects: 38
Study: 27367821

Group type: EXPERIMENTAL
Intervention: Exercise counseling plus pedometer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pedometer use
Number of subjects: 0
Study: 25391138

Group type: EXPERIMENTAL
Intervention: Alginate beads mixed into jelly
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ferrous gluconate in a capsule
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Test meals with calcium (n = 9)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alginate and cola jelly in Caco-2 cells
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of cola jelly and calcium
Number of subjects: 15
Study: 22678316

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (19 patients)
Number of subjects: 19
Study: 20299316

Group type: EXPERIMENTAL
Intervention: Eribulin monotherapy in Study 305
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Treatment of physician's choice in Study 305
Number of subjects: 1864

Group type: EXPERIMENTAL
Intervention: Eribulin in Study 301
Number of subjects: 1864

Group type: COMPARATOR
Intervention: Capecitabine in Study 301
Number of subjects: 1864
Study: 18585071

Group type: EXPERIMENTAL
Intervention: Low frequency magnetic field exposure for three weeks, 20 min a day, five days a week.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham exposure for three weeks, 20 min a day, five days a week.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Low frequency magnetic field exposure
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 61
Study: 15631247

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study: 11713438

Group type: EXPERIMENTAL
Intervention: Intervention group (mailed postcard and up to 4 telephone calls)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 603

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 603
Study: 9386673

Group type: EXPERIMENTAL
Intervention: RRV‐TV (4 x 10(5) plaque‐forming units per dose)
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: RRV‐S1 (4 x 10(5) plaque‐forming units per dose)
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1185
Study: 8195908

Group type: EXPERIMENTAL
Intervention: Materials-based educational intervention (48-page prevention guidebook)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 200
Study: 3585121

Group type: EXPERIMENTAL
Intervention: No serum in the insemination and growth medium (experimental group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 10% serum added to the insemination and growth medium (control group)
Number of subjects: 29
Study: 30078257

Group type: EXPERIMENTAL
Intervention: hrHPV infected subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cervical carcinoma group
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal vaginal flora
Number of subjects: 18

Group type: COMPARATOR
Intervention: Four groups (Alpha diversity)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: hrHPV infected cervical discharge
Number of subjects: 18
Study: 27146272

Group type: EXPERIMENTAL
Intervention: New or persistent Cornell product LVH at year-3
Number of subjects: 377
Study: 24562510

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Midazolam (MD)
Number of subjects: 275
Study: 22411021

Group type: EXPERIMENTAL
Intervention: Monthly automated telephone calls reminding to take glaucoma medications and a 1-time educational session with a physician.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonintervention group (no reminders or educational session).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intervention group (after the midstudy visit).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intervention and nonintervention groups (before and after the midstudy intervention visit).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Personality scales for depression and hypochondriasis.
Number of subjects: 80
Study: 21109134

Group type: EXPERIMENTAL
Intervention: Lateral recumbent head-down position
Number of subjects: 347

Group type: COMPARATOR
Intervention: Lateral recumbent horizontal position
Number of subjects: 347

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 347
Study: 18440179

Group type: EXPERIMENTAL
Intervention: Bilateral carotid artery stenting (CAS)
Number of subjects: 747

Group type: COMPARATOR
Intervention: Pivotal group (control)
Number of subjects: 747
Study: 16132877

Group type: EXPERIMENTAL
Intervention: ML-1 standardized mistletoe extract (1 ng/kg body weight, injected subcutaneously twice weekly for 60 weeks)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Patients undergoing radiotherapy
Number of subjects: 399
Study: 15170391

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 40

Group type: COMPARATOR
Intervention: Crystalloid solution
Number of subjects: 40
Study: 10910490

Group type: EXPERIMENTAL
Intervention: remifentanil infusion titrated to autonomic responses
Number of subjects: 50

Group type: COMPARATOR
Intervention: desflurane titrated to autonomic responses
Number of subjects: 50
Study: 8764802

Group type: EXPERIMENTAL
Intervention: Epinephrine plus hydrocortisone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebos (oral and intravenous)
Number of subjects: 20
Study: 1395837

Group type: EXPERIMENTAL
Intervention: NIAID vaccine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: BBPRI vaccine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: BBPRI vaccine plus HBIG
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 3906783

Group type: EXPERIMENTAL
Intervention: Prilocaine 2% with adrenaline 1:200,000
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lidocaine 2% with adrenaline 1:200,000
Number of subjects: 20
Study: 30800684

Group type: EXPERIMENTAL
Intervention: Outpatient diabetes self-management education programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (regular health education programmes)
Number of subjects: 60
Study: 29332470

Group type: EXPERIMENTAL
Intervention: CORE intervention (NMT program)
Number of subjects: 474

Group type: COMPARATOR
Intervention: SHAM intervention
Number of subjects: 474
Study: 26948755

Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO-marijuana
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 123
Study: 24418413

Group type: EXPERIMENTAL
Intervention: Self-monitoring group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 22369287

Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg bid
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg qd
Number of subjects: 438

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 438
Study: 20800079

Group type: COMPARATOR
Intervention: Multi-media intervention for physical activity, fruit and vegetable consumption, and limited TV viewing
Number of subjects: 1800
Study: 17690600

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12916869

Group type: EXPERIMENTAL
Intervention: Iseganan 9 mg, oral rinse, swished/swallowed 6 times daily for 21-28 days
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo, oral rinse, swished/swallowed 6 times daily for 21-28 days
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Iseganan
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 10617707

Group type: EXPERIMENTAL
Intervention: Midazolam nasal spray (0.2 mg/kg body weight)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 8885584

Group type: EXPERIMENTAL
Intervention: Methylphenidate (individual titration to 'best' dose)
Number of subjects: 576
Study: 1524922

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Wedge mastectomy
Number of subjects: 135
Study: 3878631

Group type: EXPERIMENTAL
Intervention: Combination therapies including Sucralfate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine, Pirenzepine, Ranitidine (used alone)
Number of subjects: 8
Study: 31770139

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 28472693

Group type: EXPERIMENTAL
Intervention: CRH (100μg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 31
Study: 25932849

Group type: EXPERIMENTAL
Intervention: 2 g cefazolin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 3 g cefazolin
Number of subjects: 57
Study: 23357835

Group type: EXPERIMENTAL
Intervention: Test product (Rapiflox®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference product (Avelox®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Test/Reference
Number of subjects: 20
Study: 21278001

Group type: EXPERIMENTAL
Intervention: Custom-designed education program on co-enrollment
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Shared electronic database between research units
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Interviews with ineligible enrolled women
Number of subjects: 398
Study: 19583757

Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 1090
Study: 17407626

Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: paroxetine 40 mg/day
Number of subjects: 466

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 466
Study: 15159237

Group type: EXPERIMENTAL
Intervention: Fruveg group (600 g fruit and vegetables/d)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Supplement group (vitamin pill corresponding to 600 g fruit and vegetables)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo group (placebo pill)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fruveg group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Supplement group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fruveg group and Supplement group
Number of subjects: 43
Study: 10960628

Group type: COMPARATOR
Intervention: Unopposed E2 1 mg
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.1 mg
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.25 mg
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.5 mg
Number of subjects: 1176
Study: 8829097

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study: 1310645

Group type: EXPERIMENTAL
Intervention: Soya fibers (7 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cellulose (7 g)
Number of subjects: 8
Study: 6239881

Group type: EXPERIMENTAL
Intervention: Mastisol
Number of subjects: 19

Group type: COMPARATOR
Intervention: compound tincture of benzoin
Number of subjects: 19